Arsanis, Inc. (ASNS) Hits All-Time Low

June 29, 2018 - By Nicole Mills

Arsanis, Inc. (NASDAQ:ASNS) reached all time low on Jun, 29 with $3.48 PT or 7.00 % below the last $3.74 share price. Barchart.com published the all time low. The company has $53.46M market cap. At $3.48 PT, the company’s valuation could be $3.74M less.

ASNS is reaching $3.74 during the last trading session, after decreased 6.50%.Arsanis, Inc. has 289,279 shares volume, 429.35% up from normal. ASNS is and has moved 0.00% since June 29, 2017. The stock underperformed the S&P 500 by 12.57%.

Earnings report for Arsanis, Inc. (NASDAQ:ASNS) is expected on August, 9., Faxor reports. After $-0.74 EPS report previous quarter, Wall Street now predicts 6.76 % negative EPS growth of Arsanis, Inc..

For more Arsanis, Inc. (NASDAQ:ASNS) news brought out recently go to: Schaeffersresearch.com, Nasdaq.com, Benzinga.com, Schaeffersresearch.com or Benzinga.com. The titles are as follows: “2 Healthcare Stocks Getting Buried; Option Bulls Cheer MRVL Spike” brought out on June 28, 2018, “Mid-Afternoon Market Update: Dow Rises Over 100 Points; Progress Software Shares Spike Higher” on June 28, 2018, “Mid-Day Market Update: Crude Oil Up Over 1%; Pier 1 Imports Shares Plummet” with a publish date: June 28, 2018, “Dow Futures Sink After GDP” and the last “24 Stocks Moving In Friday’s Pre-Market Session” with publication date: June 29, 2018.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases.The firm is worth $53.46 million. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.Currently it has negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis, Inc. (NASDAQ:ASNS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.